Loading
Osimertinib + Chemotherapy / Osimertinib / Stage III Lung Cancer · Observational Study
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for an active prospective observational study comparing real-world outcomes of osimertinib monotherapy versus osimertinib plus chemotherapy in EGFR-mutant NSCLC (stages III–IV). No results have been posted in this registry record; the study is currently enrolling or recently closed to enrollment, and outcome data are not yet available for clinical interpretation.
Observational. Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer; age from 18 Years. Intervention: Group 1; Group 2. Compared with: Osimertinib monotherapy versus osimertinib plus chemotherapy. n = 200. 146 sites: United States.
This is a registry record for an active prospective observational study comparing real-world outcomes of osimertinib monotherapy versus osimertinib plus chemotherapy in EGFR-mutant NSCLC (stages III–IV). No results have been posted in this registry record; the study is currently enrolling or recently closed to enrollment, and outcome data are not yet available for clinical interpretation.
Effect sizes, safety data, comparative efficacy, and hazard ratios are not reported in this registry record.
The source did not state who this applies to in practice.
This is a registry record for an active observational study with no results posted; it describes planned enrollment and methods only, without outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06538038). This is a study registration, not published results. Lead sponsor: PrECOG, LLC.. Recruitment status: ACTIVE_NOT_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 200 participants (ACTUAL). Conditions: Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer. Interventions: DRUG: Osimertinib; DRUG: Osimertinib + Chemotherapy. Primary outcome measures: real-world Progression-Free Survival (rwPFS) , From initiation of therapy to progression or death, up to 3 years. Brief summary: The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.